Contact
Please use this form to send email to PR contact of this press release:
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
TO:
Please use this form to send email to PR contact of this press release:
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
TO: